Last reviewed · How we verify
Pertuzumab Injection
Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.
Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling. Used for HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy), HER2-positive early-stage breast cancer (neoadjuvant and adjuvant settings).
At a glance
| Generic name | Pertuzumab Injection |
|---|---|
| Also known as | Perjeta |
| Sponsor | RemeGen Co., Ltd. |
| Drug class | HER2 inhibitor monoclonal antibody |
| Target | HER2 (Human Epidermal Growth Factor Receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pertuzumab targets the extracellular domain II of HER2, a different epitope than trastuzumab, and prevents HER2 from forming heterodimers with HER3 and other HER family members. This dual blockade mechanism—combined with trastuzumab's direct HER2 inhibition—provides complementary anti-tumor activity. The drug is used in combination with trastuzumab and chemotherapy to enhance efficacy in HER2-positive cancers.
Approved indications
- HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)
- HER2-positive early-stage breast cancer (neoadjuvant and adjuvant settings)
Common side effects
- Diarrhea
- Nausea
- Fatigue
- Vomiting
- Rash
- Left ventricular dysfunction
- Febrile neutropenia
Key clinical trials
- A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 and EU-Phesgo®. (PHASE1)
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer (PHASE2, PHASE3)
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (PHASE3)
- Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
- Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer (PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |